The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy

References

• Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69:2685-93; PMID:19258510; http://dx.doi.org/10.1158/0008-5472.CAN-08-2654
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424
   PubMed Web of Science ®Google Scholar
• Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009; 45:2138-45; PMID:19409772; http://dx.doi.org/10.1016/j.ejca.2009.04.011
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009; 249:788-93; PMID:19387324; http://dx.doi.org/10.1097/SLA.0b013e3181a3e738
   PubMed Web of Science ®Google Scholar
• Turner N, Wong HL, Templeton A, Tripathy S, Whiti Rogers T, Croxford M, Jones I, Sinnathamby M, Desai J, Tie J et al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer 2016; 138:671-8; PMID:26270488; http://dx.doi.org/10.1002/ijc.29805
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57; PMID:9823339
   PubMed Web of Science ®Google Scholar
• Chang EY, Dorsey PB, Frankhouse J, Lee RG, Walts D, Johnson W, Anadiotis G, Johnson N. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. Arch Surg 2009; 144:511-5; PMID:19528382; http://dx.doi.org/10.1001/archsurg.2009.40
   PubMedGoogle Scholar
• Lyerly HK, Hobeika A, Niedzwiecki D, Osada T, Marshall J, Garrett CR, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ et al. A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29(suppl): abstr 2533
   Google Scholar
• Morse M, Niedzwiecki D, Marshall J, Garrett CR, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika A et al. Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29(suppl): abstr 3557
   Google Scholar
• Balint JP, Gabitzsch ES, Rice A, Latchman Y, Xu Y, Messerschmidt GL, Chaudhry A, Morse MA, Jones FR. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother 2015; 64:977-87; PMID:25956394; http://dx.doi.org/10.1007/s00262-015-1706-4
   PubMed Web of Science ®Google Scholar
• Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006; 12:3416-24; PMID:16740766; http://dx.doi.org/10.1158/1078-0432.CCR-05-2732
   PubMed Web of Science ®Google Scholar
• von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7:1181-91; PMID:11350882
   PubMed Web of Science ®Google Scholar
• Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33:991-8; PMID:20948437; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14:6674-82; PMID:18927310; http://dx.doi.org/10.1158/1078-0432.CCR-07-5212
   PubMed Web of Science ®Google Scholar
• Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx.doi.org/10.1158/0008-5472.CAN-09-3278
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332
   PubMed Web of Science ®Google Scholar
• Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2013; 2:e27025; PMID:24353914; http://dx.doi.org/10.4161/onci.27025
   PubMed Web of Science ®Google Scholar
• Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012; 130:1948-59; PMID:21633954; http://dx.doi.org/10.1002/ijc.26219
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 2011; 60:1227-42; PMID:21544650; http://dx.doi.org/10.1007/s00262-011-1020-8
   PubMed Web of Science ®Google Scholar
• Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- vs. post-vaccination. Cancer Immunol Immunother 2011; 60:197-206; PMID:20976449; http://dx.doi.org/10.1007/s00262-010-0927-9
   PubMed Web of Science ®Google Scholar
• Ferlosio A, Arcuri G, Doldo E, Scioli MG, De Falco S, Spagnoli LG, Orlandi A. Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis 2012; 224:51-7; PMID:22857896; http://dx.doi.org/10.1016/j.atherosclerosis.2012.07.016
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27:1814-21; PMID:19273709; http://dx.doi.org/10.1200/JCO.2008.18.2071
   PubMed Web of Science ®Google Scholar
• Garcia-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno DD, Pagan-Gomez I, Rodriguez-Braun E, Perez-Guillermo M. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int J Cancer 2012; 131:1790-9; PMID:22287190; http://dx.doi.org/10.1002/ijc.27454
   PubMed Web of Science ®Google Scholar